 |
|
UT Rheumatologists Discover Two Genes
October 22, 2007Work done in part by researchers at The University of Texas Medical School at Houston has led to the discovery of two genes that cause ankylosing spondylitis, an inflammatory and potentially disabling disease. The findings are published in the Oct. 21 online edition of Nature Genetics, a journal that emphasizes research on the genetic basis for common and complex diseases.
John D. Reveille, M.D., professor and director of the Division of Rheumatology and Clinical Immunogenetics, in conjunction with Matthew A. Brown, M.D., professor of immunogenetics at Australia's University of Queensland, led research done by the Triple "A" Spondylitis Consortium Genetic Study (i.e. the TASC or Australo-Anglo-American Spondylitis Consortium).
The international team of researchers worked with investigators from the British Wellcome Trust Case Control Consortium, and together they made the genetic discovery.
Reveille, chief of rheumatology at Memorial Hermann - Texas Medical Center, said the discovery of genes ARTS1 and IL23R brings the scientific community two steps closer to fully understanding ankylosing spondylitis or AS, a chronic form of arthritis that attacks the spine and also can target other joints and organs in the body.
"We've long known that the HLA-B27 gene accounts for 40 percent of the overall cause of AS," said Reveille, the principal investigator of TASC. "Now we have found two new genes. Together with HLA-B27, these genes account for roughly 70 percent of the overall cause. That means we've almost nailed this disease. Within the next year, I predict we will have identified all the genes that play a role in this insidious disease. There is more exciting news to come."
The recent discovery is based on work from the largest and most comprehensive genome-wide association scan conducted to date. In this part of the research project, investigators were searching for genetic information related to AS, as well as autoimmune thyroid disease/Graves' Disease, breast cancer and multiple sclerosis. Reveille, the George S. Bruce, Jr. Professor in Arthritis and Other Rheumatic Diseases, said the most significant findings were in AS, a disease that generally strikes patients in their teens, 20s or 30s.
ARTS1 and IL23R show a new pathway of causation, Reveille said, and this could lead to new therapies for the arthritic condition, which can cause a complete fusion of the spine, leaving patients unable to straighten and bend.
The identification of the two new genes also could help physicians identify patients who are at the highest risk for developing AS.
"For example, if you have a family member with AS, a simple blood test would be able to tell us if you are also at risk," Reveille said. "We could offer screenings for people with back pain. In the past, the HLA-B27 test was all we had. Now we potentially have more tests."
Steve Haskew, who has lived with AS for thirty years, said the genetic discovery offers hope to patients - especially those who are newly diagnosed.
"When I first started experiencing problems - lower back pain, the aching joints - no one could tell me what was wrong," said Haskew, 59, co-leader of an AS support group that meets every other month at the UT Medical School at Houston. "It took 10 years before a rheumatologist diagnosed me with AS. Back then, there weren't many options. I was told to take anti-inflammatories and stay as active as possible. It's fascinating to see how far we've come and how much has been learned about the disease since then."
The research done by Reveille and his colleague Xiaodong Zhou, M.D., associate professor of medicine in Division of Rheumatology and Clinical Immunogenetics, was supported in part by the Center for Clinical and Translational Sciences (CCTS) at The University of Texas Health Science Center at Houston.
"This is a success story for genetics work, and I think it will lead the way for other work to be done," Reveille said.
The Spondylitis Association of America (SAA) oversaw the nationwide recruitment of patients and families for the study.
"This is the most significant breakthrough in AS genetic research since HLA-B27 was uncovered 34 years ago, and SAA played a significant role in making the study possible," said SAA Associate Executive Director Laurie Savage, who is co-principal investigator for TASC's administrative core.
The University of Texas Medical School at Houston
Reveille, chief of rheumatology at Memorial Hermann - Texas Medical Center, said the discovery of genes ARTS1 and IL23R brings the scientific community two steps closer to fully understanding ankylosing spondylitis or AS, a chronic form of arthritis that attacks the spine and also can target other joints and organs in the body.
"We've long known that the HLA-B27 gene accounts for 40 percent of the overall cause of AS," said Reveille, the principal investigator of TASC. "Now we have found two new genes. Together with HLA-B27, these genes account for roughly 70 percent of the overall cause. That means we've almost nailed this disease. Within the next year, I predict we will have identified all the genes that play a role in this insidious disease. There is more exciting news to come."
The recent discovery is based on work from the largest and most comprehensive genome-wide association scan conducted to date. In this part of the research project, investigators were searching for genetic information related to AS, as well as autoimmune thyroid disease/Graves' Disease, breast cancer and multiple sclerosis. Reveille, the George S. Bruce, Jr. Professor in Arthritis and Other Rheumatic Diseases, said the most significant findings were in AS, a disease that generally strikes patients in their teens, 20s or 30s.
ARTS1 and IL23R show a new pathway of causation, Reveille said, and this could lead to new therapies for the arthritic condition, which can cause a complete fusion of the spine, leaving patients unable to straighten and bend.
The identification of the two new genes also could help physicians identify patients who are at the highest risk for developing AS.
"For example, if you have a family member with AS, a simple blood test would be able to tell us if you are also at risk," Reveille said. "We could offer screenings for people with back pain. In the past, the HLA-B27 test was all we had. Now we potentially have more tests."
Steve Haskew, who has lived with AS for thirty years, said the genetic discovery offers hope to patients - especially those who are newly diagnosed.
"When I first started experiencing problems - lower back pain, the aching joints - no one could tell me what was wrong," said Haskew, 59, co-leader of an AS support group that meets every other month at the UT Medical School at Houston. "It took 10 years before a rheumatologist diagnosed me with AS. Back then, there weren't many options. I was told to take anti-inflammatories and stay as active as possible. It's fascinating to see how far we've come and how much has been learned about the disease since then."
The research done by Reveille and his colleague Xiaodong Zhou, M.D., associate professor of medicine in Division of Rheumatology and Clinical Immunogenetics, was supported in part by the Center for Clinical and Translational Sciences (CCTS) at The University of Texas Health Science Center at Houston.
"This is a success story for genetics work, and I think it will lead the way for other work to be done," Reveille said.
The Spondylitis Association of America (SAA) oversaw the nationwide recruitment of patients and families for the study.
"This is the most significant breakthrough in AS genetic research since HLA-B27 was uncovered 34 years ago, and SAA played a significant role in making the study possible," said SAA Associate Executive Director Laurie Savage, who is co-principal investigator for TASC's administrative core.
The University of Texas Medical School at Houston
Ankylosing Spondylitis Current Events and Ankylosing Spondylitis News RSSCV risk management should be mandatory in RA and other types of inflammatory rheumatic disease
Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients should undergo compulsory cardiovascular (CV) risk management and existing CV risk calculators should be adapted to the increased CV risk in inflammatory rheumatic disease patients.
New findings show Enbrel significantly reduced levels of C-reactive protein
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment.
Phase 3 data show golimumab improved psoriatic arthritis symptoms
Patients with active psoriatic arthritis receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) experienced significant and sustained improvements in the joint and skin manifestations of the disease.
Golimumab significantly reduced signs and symptoms of ankylosing spondylitis
More than half of patients receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) 50 mg and 100 mg experienced significant and sustained improvements in the signs and symptoms of active ankylosing spondylitis, according to Phase 3 study results presented at the American College of Rheumatology (ACR) annual meeting.
Study reveals 2 genes linked to disabling arthritis
An international team of researchers led by a Fred Hutchinson Cancer Research Center geneticist has discovered two genes linked to a disabling form of arthritis called ankylosing spondylitis, a painful and progressive disease in which some or all of the spine's vertebrae fuse together.
Major genetic breakthrough for ankylosing spondylitis brings treatment hope
Research funded by the Wellcome Trust and the Arthritis Research Campaign has identified two genes implicated in the disease ankylosing spondylitis, a common disease primarily causing back pain and progressive stiffness.
Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
Clinical data presented today at the annual meeting of the American College of Gastroenterology (ACG) show that REMICADE significantly reduces the incidence of colectomy surgeries for patients with moderately to severely active ulcerative colitis (UC).
Largest ever study of genetics of common diseases published today
The Wellcome Trust Case Control Consortium, the largest ever study of the genetics behind common diseases such as diabetes, rheumatoid arthritis and coronary heart disease, today publishes its results in the journals Nature and Nature Genetics.
Monoclonal antibody reduces exacerbations in asthmatics
Patients with symptomatic moderate asthma who were treated with anti-tumor necrosis factor alpha, an anti-inflammatory monoclonal antibody, experienced significantly fewer disease exacerbations than individuals taking a placebo.
NICE gives backing for the use of advanced biological therapies to treat severe psoriasis
The UK National Institute for Health and Clinical Excellence (NICE) has today issued guidance for the use of the targeted biological therapies, Enbrel® (etanercept) and Raptiva® (efalizumab), to treat adult patients with severe plaque psoriasis.
More Ankylosing Spondylitis Current Events and Ankylosing Spondylitis News Articles
 | Ankylosing Spondylitis: The Facts (The Facts Series) by Muhammad Asim Khan Ankylosing spondilitis is a chronic form of arthritis known to affect around 1 in 200 people(over 1 million sufferers in the USA alone). Ankylosing spondilitis: the facts is the first mass market book to be published on this important disease written by someone who is not only a leading expert on AS, but is affected by it... |
 | Ankylosing Spondylitis (Fast Facts) by Maxime Dougados, Desiree, M.D. van der Heijde Ankylosing Spondylitis is an insidious disease that is often difficult to diagnose in the early stages but can cause progressive and sometimes severe disability. This handbook, written by international experts, clearly describes the features of ankylosing spondylitis and emphasizes the importance of accurate assessment. It then discusses the evidence regarding the evidence regarding the efficiacy... |
| Ankylosing Spondylitis (Oxford American Respiratory Library) by Muhammad Asim Khan Ankylosing Spondylitis (AS) and related diseases called spondyloarthropathies (SpA) are the second most common form of chronic inflammatory arthritis after Rheumatoid Arthritis (RA). Unfortunately, most patients with AS and SpA are either never diagnosed, or they are inadequately treated. The current mean delay in the diagnosis of AS ranges from 5 to 10 years, and the presenting clinical... | |
 | 21st Century Complete Medical Guide to Ankylosing Spondylitis, Authoritative CDC, NIH, and FDA Documents, Clinical References, and Practical Information for Patients and Physicians (CD-ROM) by PM Medical Health News This up-to-date electronic book on CD-ROM provides the best collection available anywhere of official Federal government information and documents on the subject of Ankylosing Spondylitis (AS). This CD-ROM uses next-generation search technology that allows complete indexing and makes all files on the disc fully searchable. For patients, practical information is provided in clearly written patient... |
 | Ankylosing Spondylitis and the Spondyloarthropathies: A Companion to Rheumatology 3E by Michael H. Weisman, John D. Reveille, Desiree van der Heijde Developed as a companion text to the 3rd Edition of the heralded Rheumatology, by Hochberg et al., this state-of-the-art reference presents today's understanding of the spondylarthropathies. You'll find thorough examinations of the innovative, new treatments that challenge older concepts of treatment and management of the disease. Noted experts in the field also present the latest concepts in... |
 | Ankylosing Spondylitis: Diagnosis and Management The first and only interdisciplinary guide dedicated to the subject, this reference leads readers through the pathogenic, genetic, clinical, and biomechanical aspects of ankylosing spondylitis (AS). It also addresses issues related to outcomes assessment, medical treatment, surgical complications, disease management, and genetics. Detailing current treatment options and clinical essentials, this... |
 | Ankylosing Spondylitis Medical Guide by Qontro Medical Guides The Ankylosing Spondylitis Medical Guide is a publication which has been designed to better help readers understand Ankylosing Spondylitis. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Ankylosing Spondylitis. The Ankylosing Spondylitis Medical Guide is highly recommended for those... |
 | Ankylosing Spondylitis - A Bibliography and Dictionary for Physicians, Patients, and Genome Researchers by Philip M. Parker In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing.... |
| Ankylosing spondylitis: Discussions in patient management by Andrei Calin | |
| ANKYLOSING SPONDYLITIS: A PORTRAIT SURVEY. (SIGNED). |
| © 2009 BrightSurf.com |